NCT01416870View on ClinicalTrials.gov

Bioequivalence of Bicalutamide New Formulation in Japan

PHASE1TerminatedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Healthy
Interventions
DRUG

ICI176,334-1

Subject will receive single dose of ICI176,334-1

DRUG

Casodex 80 mg tablet

Subject will receive single dose of Casodex 80 mg tablet

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01416870 - Bioequivalence of Bicalutamide New Formulation in Japan | Biotech Hunter | Biotech Hunter